Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 476 - 500 of 15128 in total

Riluzole

A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
Approved
Investigational
Matched Description: … A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong …
Matched Categories: … Excitatory Amino Acid Agents ... Excitatory Amino Acid Antagonists …

Ceftriaxone

Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges , eyes , and inner ear . Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone...
Approved
Matched Iupac: … tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …
Matched Description: … meninges[A215582], eyes[A215647], and inner ear[A215627]. ... [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the ... Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins …
Matched Products: … Ceftriaxone and Dextrose …

Simeprevir

Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United...
Approved
Matched Description: … simeprevir-specific amino acid position of 168 also results in higher treatment failure rates [A19630 ... It is shown to display synergistic effects with interferon-α and HCV NS5B inhibitor, and additive effects ... The SVR12 was 83% (29/35) in treatment-naïve patients and 86% (19/22) in relapsing patients. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Resmetirom

Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. …

Rifaximin

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of...
Approved
Investigational
Matched Description: … It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction ... encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and …
Matched Categories: … Alimentary Tract and Metabolism …

Triclocarban

Triclocarban, with the chemical formula C13H9Cl3N2O is an antibacterial agent that is particularly effective against Gram-positive bacteria such as Staphylococcus aureus. It is a bacteriostatic compound that has been found in antibacterial soaps and other personal care products. In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer...
Approved
Matched Description: … It is a bacteriostatic compound that has been found in antibacterial soaps and other personal care products …

Dihydro-alpha-ergocryptine

Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. Both compounds are hydrogenated ergot derivatives. Alpha-dihydroergocryptine approved drug product...
Approved
Matched Description: … Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine ... This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine …

Formoterol

Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers....
Approved
Investigational
Matched Description: … [L10986] It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic ... mixture of its active (R;R)- and inactive (S;S)-enantiomers. ... Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was …
Matched Mixtures name: … Budesonide and Formoterol Fumarate Dihydrate ... Budesonide and Formoterol Fumarate Dihydrate ... Budesonide and Formoterol Fumarate Dihydrate …
Matched Categories: … formoterol and mometasone ... formoterol and budesonide ... formoterol and fluticasone ... formoterol and beclometasone ... formoterol and aclidinium bromide …

Asparaginase Erwinia chrysanthemi

Asparaginase Erwinia chrysanthemi is an asparaginase-specific enzyme derived from Erwinia chrysanthemi used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in...
Approved
Investigational
Matched Description: … It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA ... synthesis and cell survival of malignant cells, leading to cell death. ... [L1448] L-asparaginase was first identified in 1963,[A236344] and there are different formulations of …
Matched Categories: … Enzymes and Coenzymes …

Raloxifene

Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM....
Approved
Investigational
Matched Description: … uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. ... and it does not cause endometrial proliferation. ... generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Propofol

Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness,...
Approved
Investigational
Vet approved
Matched Description: … for induction and/or maintenance of anaesthesia prior to and during surgeries. ... Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia ... effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. …
Matched Categories: … Hypnotics and Sedatives …

Pitolisant

Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Description: … [L8063] Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized ... [A32023] Adolescent patients with cataplexy also experienced a slight improvement in the frequency and ... treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and …

Patent Blue

Patent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979....
Approved
Matched Description: … Patent blue is aniline dye and it is one of the most common dyes used. ... Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979. …

Sulfametopyrazine

Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.
Approved
Withdrawn
Matched Description: … Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria …
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... artesunate, sulfalene and pyrimethamine ... Gynecological Antiinfectives and Antiseptics ... Antiparasitic Products, Insecticides and Repellents …

Mogamulizumab

Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically...
Approved
Investigational
Matched Description: … antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and ... Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare ... Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Sincalide

Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion...
Approved
Matched Description: … It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK- ... Furthermore, sincalide stimulates the pancreatic secretion of bicarbonate and enzymes. ... Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Desonide

A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.
Approved
Investigational
Matched Categories: … desonide and antiseptics …

Phentermine

Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to...
Approved
Illicit
Matched Description: … Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity ... [A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical ... [A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely …
Matched Categories: … Alimentary Tract and Metabolism ... phentermine and topiramate …

Benzphetamine

A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Approved
Illicit

Liotrix

Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion....
Approved
Matched Description: … and combination hormone replacement therapy generally offers no therapeutic advantage. ... It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in ... It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

D-Methionine

Approved
Experimental
Investigational
Matched Iupac: … (2R)-2-amino-4-(methylsulfanyl)butanoic acid …

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …

Vernakalant

Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and...
Approved
Investigational
Matched Description: … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April …

Droxidopa

Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a...
Approved
Investigational
Matched Iupac: … (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid …
Matched Description: … associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is the ... It is approved for use in Japan and is currently in trials in the U.S. ... The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated …
Matched Categories: … Epinephrine and similars ... Adrenergic and Dopaminergic Agents ... Amino Acids, Peptides, and Proteins …

Hydroxyamphetamine

Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry...
Approved
Matched Description: … night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and …
Displaying drugs 476 - 500 of 15128 in total